Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Non Operating Income: 2018-2024

Historic Non Operating Income for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $16.1 million.

  • Allogene Therapeutics' Non Operating Income fell 36.12% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 94.84%. This contributed to the annual value of $16.1 million for FY2024, which is 190.00% up from last year.
  • Per Allogene Therapeutics' latest filing, its Non Operating Income stood at $16.1 million for FY2024, which was up 190.00% from -$17.8 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Non Operating Income registered a high of $16.1 million during FY2024, and its lowest value of -$67.3 million during FY2020.
  • Moreover, its 3-year median value for Non Operating Income was -$9.4 million (2022), whereas its average is -$3.7 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Non Operating Income plummeted by 487.89% in 2020, and later spiked by 190.00% in 2024.
  • Allogene Therapeutics' Non Operating Income (Yearly) stood at -$67.3 million in 2020, then surged by 94.69% to -$3.6 million in 2021, then slumped by 164.32% to -$9.4 million in 2022, then crashed by 88.85% to -$17.8 million in 2023, then spiked by 190.00% to $16.1 million in 2024.